Arbutus Biopharma Corp (ABUS)’s stock has witnessed a price declined of -0.42% from the previous close with its current price standing at $4.69. Its current price is -8.04% under its 52-week high of $5.10 and 73.38% more than its 52-week low of $2.70. Based on the past 30-day period, the stock price is -4.55% below the high and +15.12% above the low.
The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, ABUS’s SMA-200 is $3.62.
Additionally, it is important to take into account ABUS stock ratios, including its price-to-sales ratio, which is 58.31 for the last tewlve months.ABUS’s price to book ratio for the most recent quarter was 10.83, resulting in an 9.17 price to cash per share for the period.
How does Arbutus Biopharma Corp (ABUS) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. Currently, there are 5 brokerage firms that recommend the stock as a Moderate Buy. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1. Using a scale of 1-5, the current average recommendation is 4.20 in simple terms.
Arbutus Biopharma Corp (NASDAQ: ABUS) Ownership Details
I will give a breakdown of the key shareholders in Arbutus Biopharma Corp (ABUS). Recent figures show that the company’s insiders hold 21.87% of shares. A total of 227 institutional investors hold shares in the company, making 62.50% of its stock and 80.00% of its float.
Jun 30, 2025, it was reported that the Company’s largest institutional holder is Morgan Stanley holding total of 24.16 shares that make 12.60% of the company’s total number of shares and are currently priced at 113.44 million.
The securities firm Whitefort Capital Management, LP holds 13.34 shares of ABUS, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 6.96%, and the holding percentage of shares is valued at 62.65 million.
An overview of Arbutus Biopharma Corp’s technicals
In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests Arbutus Biopharma Corp (ABUS) traded 909,056 shares per day, with a moving average of $4.55 and price change of +0.25. With the moving average of $4.45 and a price change of +0.79, about 1,167,153 shares changed hands on average over the past 50 days. Finally, ABUS’s 100-day average volume is 1,014,365 shares, alongside a moving average of $3.90 and a price change of +1.31.
